Answers are grounded in this paper and cite their sources.
Staphylococcus aureus is the most common non-gonococcal aetiology of septic arthritis. The efficacy of iclaprim against S. aureus LS-1, a clinical strain identified from a patient with septic arthritis, was studied in MF1 mice to evaluate the activity of iclaprim, which is in clinical development, in preventing joint infections. Iclaprim (2.5–80 mg kg − 1 ) administered as a single dose via the tail vein reduced the incidence of S. aureus septic arthritis and mortality in an experimental murine model of septic arthritis.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: